title: [Efficacy and safety of GnRH-a combine with laparoscope conservative surgery in the treatment of the moderate or severe endometriosis].
abstract: OBJECTIVE
  To study the efficacy and safety of Gonadotropin-releasing hormone agonists (GnRH-a) combined with laparoscope conservative surgery in treatment of moderate or severe endometriosis.
  
  
  METHODS
  From Jan. 2007 to Jan. 2010, 68 patients with moderate or severe undergoing treatment in Renmin Hospital of Wuhan University were enrolled in this retrospective study. Three groups were classified, which were 25 patients in GnRH-a group, subcutaneous injection Leuprorelin on the second day of menstruation, every 4 weeks for 3 months. Twenty-three patients in Marvelon group, orally one marvelon tablet on the second day of menstruation, continuous 21 days for one period of treatment for 3 courses. Twenty patients in surgery group, without any medicine used preoperatively. All patients were followed by 12 months and compare their surgery time, blood loss, recovery, visual analog scale (VAS), and recurrence and so on.
  
  
  RESULTS
  The operating time were (68 ± 18) min in GnRH-a group, (80 ± 21) min in Marvelon group and (90 ± 24) min in surgery group. The amount of bleeding were (118 ± 15) ml in GnRh-a group, (161 ± 18) ml in Marvelon group and (193 ± 13) ml in surgery group. There was significant lower in the operating time and amount of bleeding in GnRH-a group than those in other two groups (P < 0.05). The activity time and the anus exhaust time were shorter in patients in GnRh-a group than those in the other two groups significantly (P < 0.05). When followed up in 12 months after treatment, visual analogue scale had dropped from 3.8 (1.9 - 6.8) to 1.9 (1.1 - 2.8) in GnRh-a group, from 2.7 (1.3 - 5.5) to 1.8 (1.2 - 3.2) in Marvelon group and from 1.9 (1.0 - 4.9) to 1.6 (1.0 - 3.6) in surgery group. It was showed the most remarkable decreased VAS in GnRHa group when compared with the other two groups (P < 0.05). The recurrence rates were 12% (3/25) in GnRH-a group, 22% (5/23)in Marvelon group and 25% (5/25) in surgery group. It was found that the most significant lower recurrence was in GnRH-a group when compared with the other two groups (P < 0.05).
  
  
  CONCLUSIONS
  It was safe and efficacy that GnRH-a combined with laparoscopic conservative surgery were used in treatment of endometriosis. It could bring shorter operation time, less intraoperative blood loss, quick postoperative recover, the lower recurrence rate.
authors.affiliation: Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
authors.forename: Ya-juan
authors.initials: YJ
authors.lastname: Zhong
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Wen-ting
authors.initials: WT
authors.lastname: Zhang
authors.forename: Jing
authors.initials: J
authors.lastname: Cheng
authors.forename: Qiong-ying
authors.initials: QY
authors.lastname: Lü
authors.forename: Kang-kang
authors.initials: KK
authors.lastname: Zeng
mesh_terms: D000284:Administration, Oral; D000328:Adult; D017135:Desogestrel / Q000008:administration & dosage / Q000627:therapeutic use; D004414:Dyspareunia / Q000628:therapy; D004715:Endometriosis / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000819:agonists*; D006801:Humans; D007279:Injections, Subcutaneous; D010535:Laparoscopy; D016729:Leuprolide / Q000008:administration & dosage / Q000627:therapeutic use*; D061646:Operative Time; D010147:Pain Measurement; D012008:Recurrence; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D007987:Gonadotropin-Releasing Hormone; D017135:Desogestrel; D016729:Leuprolide